AOD-9604 for menopause: the growth hormone fragment for stubborn fat

AOD-9604 was originally developed as an anti-obesity drug by Metabolic Pharmaceuticals in the 1990s. It is a 16-amino-acid fragment corresponding to the C-terminus of human growth hormone — the specific region responsible for GH's fat-metabolism effects, isolated from the regions responsible for growth, glucose disruption, and IGF-1 elevation. That isolation is what makes it interesting: fat-metabolism benefits without the metabolic side effects of full GH.

What AOD-9604 does

AOD-9604 stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the storage of new fat), particularly in stubborn visceral and abdominal depots. Unlike full growth hormone or GLP-1 medications, it does not affect blood glucose, insulin, or IGF-1 in a meaningful way. It also does not stimulate muscle growth or appetite suppression — the effect is narrowly on fat metabolism.

Why it is used in menopause

• Menopause preferentially adds visceral fat, which AOD-9604 targets
• It does not disrupt glucose — safe alongside insulin resistance concerns
• It does not affect IGF-1 — compatible with women who cannot use full GH secretagogues
• It is a targeted adjunct, not a primary weight-loss tool

What the evidence shows

Human trials in the 2000s showed AOD-9604 reduced body fat and specifically abdominal fat in obese adults over 12–24 weeks. Effect sizes were modest — 1–2 kg of fat loss over 12 weeks in monotherapy trials — but the safety profile was clean. The FDA declined to approve it as a standalone obesity drug, largely because effect sizes did not meet the bar for pharmaceutical anti-obesity indications. It is now available as a compounded prescription peptide.

How it fits in a menopause weight protocol

AOD-9604 is best understood as a targeted adjunct — not a substitute for the heavy hitters. For most menopausal women dealing with significant weight gain, [GLP-1 medications](/journal/glp1-and-menopause) produce dramatically larger effects. AOD-9604 fits women who have already lost the bulk of unwanted weight and are working on stubborn visceral fat, or who cannot use GLP-1s and want a targeted fat-metabolism nudge alongside strength training and nutrition.

How it is typically used

Daily subcutaneous injection, typically morning fasted, for cycles of 12–16 weeks. Best combined with resistance training and protein-forward nutrition — the peptide releases fat from storage; training and protein preserve muscle through the deficit.

Cautions

AOD-9604 is compounded through 503A pharmacies with a physician prescription. It is not appropriate for women who are pregnant, actively trying to conceive, or with active malignancy. Because it does not affect glucose or IGF-1, monitoring is simpler than for full GH secretagogues, but a baseline metabolic panel is still standard.

The bottom line

AOD-9604 is a niche, targeted tool for stubborn menopausal fat — most useful as an adjunct after the fundamentals are in place. It is not a replacement for GLP-1 therapy, resistance training, or hormone optimization. See the [AOD-9604 reference sheet](/peptides-reference/aod-9604) or the broader [peptides overview](/journal/peptides-for-menopause).

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026